GSK3036656
Drug timelines are a Plus or Pro feature.
5 regulatory and trial events tracked for GSK3036656, covering 2019-04-19 to 2026-06-17. Get the full timeline:
Most recent: Clinical Trial Results: Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis [Phase 2]